Crews Bank & Trust Takes Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Crews Bank & Trust acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 690 shares of the medical equipment provider’s stock, valued at approximately $360,000.

Several other institutional investors and hedge funds have also made changes to their positions in ISRG. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $26,000. Godsey & Gibb Inc. lifted its stake in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the last quarter. MidAtlantic Capital Management Inc. acquired a new stake in Intuitive Surgical during the third quarter valued at approximately $33,000. Decker Retirement Planning Inc. acquired a new stake in Intuitive Surgical during the fourth quarter valued at approximately $36,000. Finally, Capital Performance Advisors LLP acquired a new stake in Intuitive Surgical during the third quarter valued at approximately $38,000. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In related news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $539.00, for a total value of $202,664.00. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,967,734. This trade represents a 6.39 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Jamie Samath sold 22,903 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the completion of the transaction, the insider now owns 8,757 shares in the company, valued at $4,597,425. The trade was a 72.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,843 shares of company stock worth $15,357,560 in the last 90 days. 0.90% of the stock is owned by insiders.

Intuitive Surgical Stock Up 1.3 %

ISRG stock opened at $580.18 on Friday. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00. The company has a market cap of $206.65 billion, a price-to-earnings ratio of 93.28, a PEG ratio of 5.19 and a beta of 1.39. The company has a 50 day moving average of $549.32 and a two-hundred day moving average of $507.50.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Leerink Partners increased their target price on shares of Intuitive Surgical from $490.00 to $548.00 in a research note on Monday. Jefferies Financial Group increased their target price on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday. JPMorgan Chase & Co. increased their target price on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Evercore ISI upped their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a research report on Monday. Finally, Oppenheimer restated a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.